Profiling and identification of novel \textit{rpoB} mutations in rifampicin-resistant \textit{Mycobacterium tuberculosis} clinical isolates from Pakistan

Mehmood Qadir\textsuperscript{a}, Sabira Tahseen\textsuperscript{b}, Timothy D McHugh\textsuperscript{c}, Alamdar Hussain\textsuperscript{b}, Faisal Masood\textsuperscript{b}, Niaz Ahmed\textsuperscript{b}, Rani Faryal\textsuperscript{a, *}

\textsuperscript{a}Department of Microbiology, Quaid-i-Azam University, Islamabad, Pakistan.
\textsuperscript{b}National TB Reference laboratory, National TB Control Program, Islamabad, Pakistan.
\textsuperscript{c}Centre for Clinical Microbiology, Division of Infection and Immunity, University College London, London.

*Corresponding Author:
Dr. Rani Faryal
Department of Microbiology, Quaid-i-Azam University, Islamabad, Pakistan
Email: ranifaryal@qau.edu.pk

ICMJE Statement: MQ, ST and RF conceived presented idea. MQ, AH, FM and NA performed experiment and analyzed data. TM and RF supervised this work. All authors contributed to the final manuscript.
Abstract

Introduction: Rifampicin (RIF) is one of the most effective anti-tuberculosis first-line drugs prescribed along with isoniazid. However, the emergence of RIF resistance *Mycobacterium tuberculosis* (MTB) isolates is a major issue towards tuberculosis (TB) control program in high MDR TB-burdened countries including Pakistan. Molecular data behind phenotypic resistance is essential for better management of RIF resistance which has been linked with mutations in *rpoB* gene. Since molecular studies on RIF resistance is limited in Pakistan, the current study was aimed to investigate the molecular data of mutations in *rpoB* gene behind phenotypic RIF resistance isolates in Pakistan.

Method: A total of 322 phenotypically RIF-resistant isolates were randomly selected from National TB Reference Laboratory, Pakistan for sequencing while 380 RIF resistance whole-genome sequencing (WGS) of Pakistani isolates (BioProject PRJEB25972), were also analyzed for *rpoB* mutations.

Result: Among the 702 RIF resistance samples, 675 (96.1%) isolates harbored mutations in *rpoB* in which 663 (94.4%) were detected within the Rifampicin Resistance Determining Region (RRDR) also known as a mutation hot spot region, including three novel. Among these mutations, 657 (97.3%) were substitutions including 603 (89.3%) single nucleotide polymorphism, 49 (7.25%) double and five (0.8%) triple. About 94.4% of Phenotypic RIF resistance strains, exhibited mutations in RRDR, which were also detectable by GeneXpert.

Conclusion: Mutations in the RRDR region of *rpoB* is a major mechanism of RIF resistance in MTB circulating isolates in Pakistan. Molecular detection of drug resistance is a faster and better approach than phenotypic drug susceptibility testing to reduce the time for transmission of RIF
resistance strains in population. Such insights will inform the deployment of anti-TB drug regimens and disease control tools and strategies in high burden settings, such as Pakistan.

Keywords: rpoB; rifampicin-resistant; Mycobacterium tuberculosis; mutations; anti-TB drug.
Introduction

Tuberculosis is among the top ten leading causes of death worldwide and, according to WHO estimates, ten million people developed TB in 2017 globally. The emergence of first-line drug-resistant tuberculosis (TB) [1,2], especially multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB, poses formidable challenges to controlling TB in high burden countries (WHO 2020, https://www.who.int/publications/i/item/9789240013131). In 2017, 558000 of global TB cases were resistant to rifampicin (RIF) [3]. RIF is one of the most effective anti-TB drugs and resistance to it serves as a valuable surrogate marker for diagnosis of multidrug-resistant tuberculosis (MDR-TB) [4]. This resistance is primarily developed through mutations in \( \text{rpoB} \) of \( \text{Mycobacterium tuberculosis} \) (MTB). In general, 96.1% of RIF resistance worldwide is associated with \( \text{rpoB} \) mutations, and >90% of these mutations are located in the 81 bp RIF resistance determining the region (RRDR) of \( \text{rpoB} \) [5,6].

Various culture-based and molecular methods are used for drug susceptibility testing in MTB. Phenotypic drug susceptibility testing (DST) is still considered the gold standard. Culture-based methods are time-consuming and deemed to be a significant obstacle for prompt diagnosis of MDR TB, its management and control [7]. RIF DST is considered to be highly reliable and accurate. However, some clinically relevant, low-level RIF resistance linked to specific \( \text{rpoB} \) mutations, can be easily missed by growth-based methods [8]. This problem, however, appears to have been solved with the development of molecular techniques [9,10]. In 2009, WHO, for the first time, recommended the use of a genotypic method including Genotype MTBDRplus (Hain Lifescience, Nehren, Germany) for rapid detection of drug-resistant TB [9] while also recommending a cartridge-based nucleic acid amplification test called Xpert® MTB/RIF (Cepheid, Sunnyvale, CA, USA) for simultaneous detection of \( \text{Mycobacterium} \)
*tuberculosis complex* (MTBC) and RIF resistance [10]. Both these commercial assays can detect mutations located within the 81 bp hotspot region of the *rpoB* and are currently being used on a global scale [9,10].

Beyond the common RRDR mutations, other significant mutations in rifampicin-resistant (RR) strains have been reported in *rpoB* [6,10–12] from 1% to 5% of total RR strains. According to the WHO report 2020 [13], half a million people developed RIF resistant TB of which 78% had MDR-TB. The three countries, India (27%), China (14%) and the Russian Federation (8%) share the largest of the global burden of 27%, 14%, and 8% respectively. Globally MDR/RR-TB was present in 3.3% of new cases and 17.7% of previously treated cases. The highest proportions was detected in previously treated cases (>50%), were in former Soviet Union countries.

Pakistan is among the five highest-burden countries for RR cases, having an estimated 15000 cases every year at the rate of 4.2% and 16% in new and previously treated cases, respectively [3]. Only a few small-scale studies, however, have been conducted in the country for the characterization of *rpoB* mutations among local MTB strains [14–16].

Phenotypic DST is considered to be the gold standard method to infer resistance. However, some studies have reported that liquid culture systems (e.g. the MGIT platform) often fail to detect low-levels of RR-TB [17,18], including those involving H445D/L/R mutations [17,19], which have been linked to treatment failure or relapse [20–22].

The aim of this study is the molecular characterization of phenotypically RR clinical isolates to determine the frequency of known as well as novel mutations within and outside the RRDR region of *rpoB*. Thes information will be useful in selecting and developing appropriate rapid diagnostic tools to aid in the management of MDR TB.
Materials and methods

Ethical Approval
The current study was ethically approved by the Quaid-e-Azam University Ethical Committee (QAU-BRC), Islamabad, Pakistan.

Setting
The National TB Reference Laboratory, Islamabad, Pakistan (NRL), provides DST services to 50% of the country’s population including the largest province (Punjab) and three regions (Islamabad Capital Region, Azad Kashmir and Gilgit Baltistan). Phenotypic DST is performed on MTB culture isolates from TB patients diagnosed as RR on GeneXpert with unknown RIF status.

Sampling
The study was conducted from January 2014 to October 2016. All MTB isolates that reported RR on phenotypic DST were identified first, and 322 (13.3%) of these were selected using sample random method for rpoB sequencing. The whole-genome sequencing (WGS) results of 380 isolates from a previous study [23] under BioProject PRJEB25972 were also available and were resistant to RIF, which were included for analysing the rpoB gene mutation.

Processing of specimens for Mycobacterial culture and DST
Clinical specimens were decontaminated using the NALC-NaOH method and were inoculated on Middlebrook 7H9 Broth (Bactect MGIT 960 tube) and Lowenstein-Jensen (LJ) Media [24]. Rapid BD MGIT™ TBc Identification testing was performed on positive cultures for confirmation of Mycobacterium tuberculosis complex (MTBC). Drug susceptibility testing was
performed on MTBC isolates using the proportion method on LJ media for RIF at 40µg/ml, 0.2 µg/ml for Isoniazid (IHN), 2.0 µg/ml for ofloxacin (OFX), 30.0 µg/ml for kanamycin (KM) [25]. Based on the DST results, MTB isolates were classified into four groups as follows: RIF mono (only RR), MDR (Resistant to both Rif and INH), Pre-XDR (MDR strain also resistant to Fluoroquinolone (FQ) or Second-line injectable (SLI) and XDR (MDR strains also resistant to FQ and SLI).

**MIC determination**

Minimum inhibitory concentration (MIC) was determined for newly reported mutations as well as some already well-characterized mutations for comparison using the Bactec MGIT 960 system and LJ media, as described in previous studies [26–29]. The drug concentrations tested for RIF included 0.125, 0.25, 0.5, 1, 2, 4, and 8 µg/mL for MGIT and 5, 10, 20, 40, 80, and 160 µg/mL for LJ media.

**PCR amplification and sequencing of rpoB**

DNA for polymerase chain reaction (PCR) was extracted by heating bacterial colonies at 90°C for 20min in 100 microliters of water followed by sonication using ELMA E-30H Sonicator (Elma Schmidbauer GmbH) for 15 minutes. PCR was performed using 25 µL of Qiagen HotStarTaq Master Mix containing 2.5 units of HotStarTaq DNA Polymerase1 x PCR Buffer (Contains 1.5 mM MgCl₂) and 200 µM of each dNTP, 2 µL of each forward and reverse 10 µM primer, 8 µL of DNA and 5 µL of water with a total volume of 50 microliter in a Gene Amp PCR systems 9700 (Applied Biosystem). PCR cycling conditions began with 15 minutes hot start, followed by 45 cycles at 94°C for 45 seconds, annealing and extension for 1 min 30 sec at 72°C, and a final amplification at 72°C for 10 min. Primers rpoBgeneSA (5' -
GGTTCGCCGCCTGGCGCGAAT-3') and rpoBgeneRB (5' -
GACCTCCTCGATGACGCCTTCTTCT-3') were used for amplification of a 1764 bp region of
the rpoB [30].

Sequencing was performed using the following primers: forward 5'-
GGGAGCGGATGACCACCCA-3', and reverse 5'-GCGGTACGGCGYTTCGATGAAC-
3'(21) on 3130 Genetic Analyser by Applied Biosystems using the BigDye™ Terminator
v3.1 Cycle Sequencing Kit at University College, London. WGS was performed on the Illumina
platform at Supranational TB Reference Laboratory (SRL) in Milan, Italy, in another study [23].

**Sequencing Analysis**

For strains on which rpoB sequencing was performed, analysis of the chromatogram generated
by the sequencer was conducted by Molecular Evolutionary Genetics Analysis Version 7
(MEGA 7) software and compared to H37Rv rpoB sequence Rv0667. PhyResSE web tool was
used for rpoB polymorphism and phylogenetic lineage analysis [31]. PhyResSE is a reliable and
simple viewer for MTB WGS DNA reads. The server combines the most reliable methods from
FastQC, SAMtools, QualiMap, BWA, and others with validated samples. Single and paired-end
data from Next Generation Sequencing of Mycobacterium tuberculosis could be analyzed with
validated approaches. Mutations were characterized using both MTBC numbering system and
the E. coli numbering system [32].

**Quality Control**

NRL participates annually in proficiency testing conducted by the WHO collaborating centre and
Supra National Reference Laboratory, ITM in Antwerp, Belgium. For internal quality control,
susceptible strain H37Rv and two known rifampicin-resistant strains selected from the DST
proficiency testing panel were included with each batch for DST.
Results

During the study period (January 2014 to October 2016), 2421 strains were reported as phenotypically resistant to RIF including 3% as mono RIF resistant, 45% MDR, 46% pre-XDR and 6% XDR (Table 1), rpoB gene sequencing was performed on 322(13.3%) isolates and already available WGS data was analysed for an additional 380(15.6%) isolates [23]. Among the 702(29%) phenotypically resistant isolates for which rpoB sequencing data was analysed, mutations in rpoB were identified in 675 isolates (96.1%), and 27 (3.8%) were reported as wild type.

Among 675 isolates with mutations in rpoB, substitutions of nucleotides were identified in 657 (97.3%), one having both substitution and deletion and 17 (2.7%) with either insertion or deletion. A total of 63 different types of polymorphism were identified including single nucleotide polymorphism (SNP) in 603 isolates (89.3%), double nucleotide polymorphism (DNP) in 49 isolates (7.25%) and triple nucleotide polymorphisms (TNP) in five (0.74%) isolates as shown in Table 2. Mutations were detected outside RRDR in 12 isolates which include mutation at Ile491Phe in 6 isolates, Ile491Met in one isolate, Ile491Leu in one isolate, Val170Phe in three isolates and a change in Tyr474His.

In the rpoB, the highest number of amino acid changes were found at position Ser450 (64.1%) followed by Asp435 (13.3%) and His445 (12.7%). The most frequent amino acid change noted was Ser450Leu (60.3%). This amino acid change was seen at a frequency of 72.2 % in XDR 61.3% in pre-XDR compared to 58.7% in MDR and isolates. Amino acid changes observed at frequencies of four times or more are shown in Table 3, while amino acid changes seen with lesser frequencies are listed in Table 3s.
In 12 isolates (1.8%), three different types of mutations were detected outside the 81 base pair hotspot region including Ile491Phe in six isolates, Ile491Met in 1 isolate, Ile491Leu in 1 isolate, Val170Phe in three isolates and a change in Tyr474His as shown in Table 3 and 3s. Mutation was located within Rifampicin resistant determining region (RRDR) in 663 (94.4%) isolates, including three new mutations identified as shown in Figure. In the RRDR region, the mutation detected was due to the insertion of arginine (R) at position 432 of rpoB (insertion codon CGC1294). In another isolate, deletion of GAA codon at position 1308-10 resulted in substitution Gln436His and deletion of amino acid asparagine (N) at 437. The mutation was detected in another isolate due to deletion of CACCAGCCAGCTG/C at 1281-1294 resulting in deletion of 4 amino acid threonine (T), serine (S), glutamine (Q) and leucine (L).

Phenotypic genotypic results, MICs, Genotypes, DST Pattern and GenBank accession numbers of newly reported mutations are summarized in Table 4. In our study, we were able to characterize 344 isolates into phylogenetic lineages. The most common lineage found in our research was Delhi/CAS in 257 cases (74.7%) followed by Euro American Super Lineage in 45(13.1%), Beijing in 20 (5.8%), EAI in 16 (4.7%), Haarlem in 2 isolates while Cameroon in one, TUR and Ural was identified in one isolates. Predominant lineage Delhi/CAS was found in 79.2% of MDR, 73.3% of pre-XDR, 61.9% in XDR and 55.6% of rifampicin mono resistant isolates.

**Discussion**

In this study, we investigated mutations occurring in the rpoB among phenotypic resistant 702 MTB isolates from Pakistan. We reported mutations in RRDR region in 663 (94.4%) isolates including three novel mutations, while outside the RRDR region were detected in 12 isolates (1.8%), whereas no mutation was identified in 27 (3.8%) of the phenotypically resistant isolates.
Mutations detected in *rpoB* were substitutions in 657 (97.3%), deletions, and insertions in 18 (2.7%) isolates. Our data is consistent with the previously reported studies in RRDR and outside RRDR [5,30,33]. In a previous study [34], five isolates did not harbor any mutation in the RRDR of RpoB region. In Swaziland 30% of RR cases, harbored mutations outside the RRDR [35]. In Uganda, 18% (8/45), in China five mutations were detected outside the RRDR region [15, 16]. Similarly, in Syria, one mutation was detected outside the RRDR region [37].

Pakistan is among the five highest-burden countries for RR cases, the most frequent mutations reported in RRDR regions were Ser450 (64.1%), Asp435 (13.3%) and His445 (12.7%). Earlier studies performed in Pakistan, were on small sample sizes, have also reported similar frequencies of changes at amino acid position 450 (52 and 56.4%), amino acid 435 (4.84% and 15%) and amino acid 445 (7 and 9.68%) [15,16]. Similar frequencies of mutations were reported by other countries in Asia, e.g., Ser450 mutation rates were reported in India (59%), China (60%) Nepal (58.7), and in Russia (66.6%). Similarly, Asp435 were reported in the range of 5.3% to 15.6% and His445 from 15.3 to 29.2% in these countries [12,38–41].

Except for the three new types of mutations we have identified in this study, other mutations have been previously reported and associated with drug resistance in different studies which are available TB dream database [42] and in a review study [11] which is part of the WHO guideline, “The use of next-generation sequencing technologies for the detection of mutations associated with drug resistance in *Mycobacterium tuberculosis* complex: technical guide”. We characterized three novel mutations, two out of these mutations (deletion of four amino acids TSQL from 427-430 and an insertion of amino acid R at position 432) were reported RIF-resistant by Xpert as well as a phenotypic method using Liquid MGIT 960 and Solid
Lowenstein Jensen media. MIC of these newly reported mutation was above critical concentration on both MGIT ang LJ media and were classified as resistant.

However, one novel mutation due to the substitution of amino acid Gln436His and deletion of Asn437 was resistant to Xpert and phenotypic DST on LJ but susceptible to Liquid MGIT 960. MIC was determined for this strain and it was 0.5 µg/ml on MGIT 960 which is below the critical concentration of 1 µg/ml and will be reported as susceptible. However, MIC on LJ media was 80 µg/ml which was above the critical concentration of 40 µg /ml and was classified as resistant. Previous studies have also reported mutations which were resistant on solid media DST while susceptible on MGIT DST [7,43]. Laboratories performing DST on MGIT only are likely to misdiagnose such cases, leading to treatment failure and proliferation of resistant strains. However, it has been reported previously that deletion of Asn437 of the M. tuberculosis RpoB causes rifampicin resistance in recombinant M. smegmatis [44].

These newly-identified mutations are very important as drug susceptibility testing is moving from phenotypic to genotypic method especially whole-genome sequencing. Once this report is published and data of these mutations is made available to those databases which identify and classify resistance causing mutations. These will be updated and once they will be identified elsewhere will get classified as resistant conferring mutations. This data will also be helpful as a lot of new diagnostics tools are in the process of development as well as getting upgraded. The sequences of the newly identified mutations have been submitted to GenBank and are available under accession numbers shown in Table 4. All mutations identified outside the RRDR region have been previously reported in different studies [11,33,42,45]. The frequency of such mutations reported in our study correlates to studies conducted in different regions [46] including Pakistan [47]. However, under-reporting of these mutations cannot be disregarded as Xpert
testing services are decentralized and RR cases are only systematically referred for DST. It is, therefore, important that samples from patients reported as rifampicin sensitive on Xpert but with poor response to treatment should be referred for phenotypic DST or sequencing to avoid misdiagnosis of resistant strains, otherwise ineffective treatment will result in proliferation and transmission of these strains. In Swaziland, 30% of RR cases were detected due to mutation outside RRDR [35].

In our work, no mutation was detected in 27 (3.8%) of the phenotypically RIF-resistant isolates (Table 1). These isolates may carry other mechanisms of resistance, such as modified efflux pumps [48,49] but the possibility of laboratory error cannot be excluded with certainty. In conclusion, our study has provided valuable information on mutations associated with resistance to rifampicin in clinical isolates from Pakistan. We were able to characterize and report the frequency of different mutations inside as well as outside RRDR in our population including three novel mutations. These findings described will help compare and evaluate the new diagnostic tools for diagnosis of MDR TB.

Conclusion

The application of sequencing technologies in TB endemic regions will assist clinical management and personalised anti-TB drug approaches, as well as disease control through surveillance activities. The management of MDR-TB strains is essential for the control of TB. In our study, we found that the mutations underlying MDR-TB are established variants. Known and putative drug resistance markers in established loci are detectable using low-cost sequencing-based approaches (e.g. amplicon-based), suitable for a low resource setting. More than 94% strains with resistance to rifampicin exhibited mutations in RRDR, detectable by Xpert and the line probe assay. Although these current molecular assays are applicable for the early detection
of rifampicin resistance in the region. However, a significant subset of mutations not detected by these rapid methods was identified, and these pose a risk for the further development of drug resistance. Failure to consider the possibility of drug-resistant TB can result in inadequate drug regimens, amplification of drug resistance, and additional disease transmission. Large-scale molecular approaches including whole genome sequencing and analysis will assist with understanding the epidemiology and risk groups or factors underpinning the transmission of TB, as well as provide insights into drug resistance and compensatory mechanisms. Such insights will inform the deployment of anti-TB drug regimens and disease control tools and strategies in high burden settings, such as Pakistan.

Acknowledgements

We will like to thank all colleagues at National TB reference, Laboratory and University College London for their help in technical assistance for DST and sequencing.

Conflict of interest statement

None of the authors has any conflict of interest with the material in this manuscript.

References


Figure legends

Figure 1: Depiction of novel mutations detected in the RpoB (hotspot region RRDR) of M. tuberculosis strains using MTB numbering system. Mutation site has been shown with blue arrows. H37Rv was used as a reference for comparison.
Table 1: **Total drug resistance and RIF resistance isolates with sequencing data**

<table>
<thead>
<tr>
<th>Phenotypic DST profiles</th>
<th>¹Total resistant isolates (2421)</th>
<th>²Total resistant isolates with sequencing data (702)</th>
<th>³Isolates with <em>rpoB</em> mutation (675)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>%</td>
<td>N</td>
</tr>
<tr>
<td>Mono RIF resistant</td>
<td>65</td>
<td>3%</td>
<td>28</td>
</tr>
<tr>
<td>MDR</td>
<td>1094</td>
<td>45%</td>
<td>305</td>
</tr>
<tr>
<td>PRE-XDR</td>
<td>1119</td>
<td>46%</td>
<td>331</td>
</tr>
<tr>
<td>XDR</td>
<td>143</td>
<td>6%</td>
<td>38</td>
</tr>
</tbody>
</table>

*N: Number.
¹Total resistant isolates recorded at National TB reference laboratory, Pakistan (NRL).
²Resistant isolates whose sequence data is available.
³RIF resistant isolates with *rpoB* mutations.
Table 2: Different types of mutations detected in *rpoB* of RIF resistant isolates.

<table>
<thead>
<tr>
<th>Mutation/polymorphism type</th>
<th>Clinical isolates with mutations (n)</th>
<th><em>Polymorphism types detected (n)</em></th>
</tr>
</thead>
<tbody>
<tr>
<td>Indels</td>
<td>Deletions</td>
<td>8</td>
</tr>
<tr>
<td></td>
<td>Insertions</td>
<td>9</td>
</tr>
<tr>
<td>Substitution</td>
<td>Single Nucleotide Polymorphism</td>
<td>603</td>
</tr>
<tr>
<td></td>
<td>Double Nucleotide Polymorphism</td>
<td>49</td>
</tr>
<tr>
<td></td>
<td>Triple Nucleotide Polymorphism</td>
<td>5</td>
</tr>
<tr>
<td>Indels + Substitution</td>
<td>Deletion + substitution</td>
<td>1</td>
</tr>
<tr>
<td>Total</td>
<td></td>
<td>675</td>
</tr>
</tbody>
</table>

*Different types at different locations of *rpoB*. N: number*
Table 3: Frequency of different mutations among various RIF resistant isolates

<table>
<thead>
<tr>
<th>Codon Change</th>
<th>A. A Change (RpoB) MTB Numbering System</th>
<th>A. A Change (RpoB) E. coli Numbering System</th>
<th>RIF-mono resistant (n=25)</th>
<th>MDR n=291</th>
<th>PRE-XDR n=323</th>
<th>XDR n=36</th>
<th>*Total n= 675 (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>TCG→TTG</td>
<td>Ser450Leu</td>
<td>Ser531Leu</td>
<td>12</td>
<td>171</td>
<td>198</td>
<td>26</td>
<td>407(60.3)</td>
</tr>
<tr>
<td>GAC→GTC</td>
<td>Asp435Val</td>
<td>Asp516Val</td>
<td>0</td>
<td>20</td>
<td>25</td>
<td>2</td>
<td>47(7.0)</td>
</tr>
<tr>
<td>TCG→TGG</td>
<td>Ser450Trp</td>
<td>Ser531Trp</td>
<td>1</td>
<td>9</td>
<td>10</td>
<td>3</td>
<td>23(3.4)</td>
</tr>
<tr>
<td>CTG→CCG</td>
<td>Leu452Pro</td>
<td>Leu533Pro</td>
<td>2</td>
<td>7</td>
<td>9</td>
<td>1</td>
<td>19(2.8)</td>
</tr>
<tr>
<td>GAC→TAC</td>
<td>Asp435Tyr</td>
<td>Asp516Tyr</td>
<td>0</td>
<td>5</td>
<td>10</td>
<td>1</td>
<td>16(2.4)</td>
</tr>
<tr>
<td>CAC→TAC</td>
<td>His445Tyr</td>
<td>His526Tyr</td>
<td>2</td>
<td>3</td>
<td>10</td>
<td>0</td>
<td>15(2.2)</td>
</tr>
<tr>
<td>CAC→GAC</td>
<td>His445Asp</td>
<td>His526Asp</td>
<td>2</td>
<td>7</td>
<td>3</td>
<td>0</td>
<td>12(1.8)</td>
</tr>
<tr>
<td>CAC→CTC</td>
<td>His445Leu</td>
<td>His526Leu</td>
<td>0</td>
<td>8</td>
<td>4</td>
<td>0</td>
<td>12(1.8)</td>
</tr>
<tr>
<td>CAC→AAC</td>
<td>His445Asn</td>
<td>His526Asn</td>
<td>0</td>
<td>4</td>
<td>4</td>
<td>0</td>
<td>8(1.2)</td>
</tr>
<tr>
<td>ATC→TTC</td>
<td>Ile491Phe</td>
<td>Ile572Phe</td>
<td>0</td>
<td>2</td>
<td>4</td>
<td>0</td>
<td>6(0.9)</td>
</tr>
<tr>
<td>Insertion of TTC→1300</td>
<td>Phe433ins</td>
<td>Phe514ins</td>
<td>1</td>
<td>3</td>
<td>2</td>
<td>0</td>
<td>6(0.9)</td>
</tr>
<tr>
<td>CAC→CGC</td>
<td>His445Arg</td>
<td>His526Arg</td>
<td>0</td>
<td>4</td>
<td>1</td>
<td>0</td>
<td>5(0.7)</td>
</tr>
<tr>
<td>CAC→TGC</td>
<td>His445Cys</td>
<td>His526Cys</td>
<td>0</td>
<td>1</td>
<td>4</td>
<td>0</td>
<td>5(0.7)</td>
</tr>
<tr>
<td>CTG→CCG</td>
<td>Leu430Pro</td>
<td>Leu511Pro</td>
<td>0</td>
<td>2</td>
<td>2</td>
<td>1</td>
<td>5(0.7)</td>
</tr>
<tr>
<td>CAA→CTA</td>
<td>Gln432Leu</td>
<td>Gln513Leu</td>
<td>0</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>4(0.6)</td>
</tr>
<tr>
<td>CAA→AAA</td>
<td>Gln432Lys</td>
<td>Gln513Lys</td>
<td>0</td>
<td>1</td>
<td>3</td>
<td>0</td>
<td>4(0.6)</td>
</tr>
<tr>
<td>CTG→CGG, GAC→TAC</td>
<td>Leu430Arg ,</td>
<td>Leu511Arg ,</td>
<td>0</td>
<td>1</td>
<td>3</td>
<td>0</td>
<td>4(0.6)</td>
</tr>
<tr>
<td>ATG→ATA</td>
<td>Met434Ile , Asp435Tyr</td>
<td>Met515Ile , Asp516Tyr</td>
<td>0</td>
<td>3</td>
<td>1</td>
<td>0</td>
<td>4(0.6)</td>
</tr>
<tr>
<td>GAC→TAC</td>
<td>Met434Val , Met515Val</td>
<td>Hi526Asn</td>
<td>2</td>
<td>0</td>
<td>2</td>
<td>0</td>
<td>4(0.6)</td>
</tr>
</tbody>
</table>

*Frequency of each mutation among total RIF resistance mutations.
#AA: Amino Acid
Table 4: Novel mutations detected in *RpoB* among RIF resistant *MTB* isolates

<table>
<thead>
<tr>
<th>Codon change *</th>
<th>Amino acid change *</th>
<th>MTB Numbering *</th>
<th>Amino acid change E.Coli Numbering</th>
<th>GX MIC E.Coli /μg</th>
<th>LJ MIC MTB /μg</th>
<th>MGIT MIC /μg</th>
<th>Type of mutation</th>
<th>Genotype</th>
<th>*Res-Type</th>
<th>GeneBank accession numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ins of cgc at 1294</td>
<td>Insertion of Arg at 432</td>
<td>R513ins (inframe)</td>
<td>R</td>
<td>&gt;80</td>
<td>2</td>
<td>Insertion</td>
<td>Delhi/CAS</td>
<td>MDR</td>
<td>MT411895</td>
<td></td>
</tr>
<tr>
<td>Caccag ccagctg /C from 1279-1290</td>
<td>deletion of aa TSQL at 427-30</td>
<td>Del T508-S509-Q510-L511 (inframe)</td>
<td>R</td>
<td>&gt;80</td>
<td>4</td>
<td>Deletion</td>
<td>Euro-American Super Linage</td>
<td>RIF-R</td>
<td>MT411896</td>
<td></td>
</tr>
<tr>
<td>CAGA AC/CA at 1308-10</td>
<td>Gln436His + Asn437del</td>
<td>Q517H+ Asn518del</td>
<td>R</td>
<td>80</td>
<td>0.5</td>
<td>Substitution + deletion</td>
<td>Delhi/CAS</td>
<td>PRE-XDR</td>
<td>MT411897</td>
<td></td>
</tr>
</tbody>
</table>

*Type of resistance. MDR; Multidrug resistance, XDR; Extensively drug resistance. #Codon change in rpoB gene. GX; GeneXpert, LJ; Lowenstein Jenson media.